Foghorn Therapeutics (FHTX) Receives a Buy from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Laura Prendergast has maintained a Buy rating on Foghorn Therapeutics (FHTX) with a price target of $12.00. Prendergast, a 5-star analyst, has an average return of 59.6% and a success rate of 61.90%. The analyst consensus for Foghorn Therapeutics is Strong Buy, with a price target consensus of $11.67.
Stifel Nicolaus analyst Laura Prendergast maintained a Buy rating on Foghorn Therapeutics today and set a price target of $12.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Prendergast is a 5-star analyst with an average return of 59.6% and a 61.90% success rate. Prendergast covers the Healthcare sector, focusing on stocks such as Erasca, BridgeBio Oncology Therapeutics, and Revolution Medicines.
Foghorn Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.67.